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Hepatitis C: an emerging concern 
D. Falzon*, A. Portelli**, C. Mallia Azzopardi***, C. Gauci* 
ABSTRACT: Hepatitis C has surfaced worldwide as a formidable concern to public health. 
Recent developments have sharpened methods of serological detectability, epidemiological study 
and patient treatment. In the light of the global situation, this article briefly presents known local 
epidemiology about hepatitis C derived from routine data and personal communication from some 
key workers. The occurrence of a serious, potentially progressive, transmissible condition in a 
young population will incur high-costs to patients, contacts and care services. The article 
concludes by highlighting the areas offering greatest scope to check this condition through 
prevention and patient management. 
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A global overview 
After many years of doubt about non-A, non-B 
hepatitis (NANBH), these last eight years have seen 
major advances in the characterisation of the hepatitis C 
virus (HCY) and substantial progress in the methodology 
of detection and disease management. 
Recent developments have underlined the main areas 
of risk associated with transmission of blood borne 
viruses. The recent history of hepatitis C has overlapped 
with that of hepatitis B virus and HIY, with which it 
shares several characteristics. 
Hepatitis C is a cosmopolitan infection, varying in 
frequency by region (Table I )1,2. Many HCY -infected 
individuals in the West are either intravenous drug users 
(lDUs), or recipients of blood products which, in the 
past, had not been screened for anti-HCy3. Before the 
introduction of blood donor screening and virus 
inacti vation methods for plasma products, infection of 
haemophiliacs was widespread owing to contamination 
of pooled clotting factor concentrates4. 
Other parenteral risks include tattooing, and needle­
stick injuries among health care workers. Needle-stick 
InJunes from HCY -viraemic patients lead to 
transmission in 3-10% of cases, a risk lying between that 
for hepatitis B virus and HIy3. Care workers acquiring 
bloodborne viruses may subsequently pose a risk of 
infecting patients. At least one episode of carer-to­
patient transmiSSIOn of hepatitis C infection is 
documented to have followed cardiac surgery in UK in 
19945. 
The first known transmission of HCY from tattooing 
occurred in 19896• Some cases of hepatitis C, without 
evident history of previous parenteral exposure, may 
have resulted from use of improperly sterilised surgical 
instruments, or by blood admixture in folk medicine3. 
Table1 - Inter-country comparison of anti-HCV 
seroprevalence in blood donors 
Country 	 % donors Year 

ELISA-1 publishrd 

positive 

Taiwan 0.28% 1991 

Turkey 0.31% 1991 

Australia 0.45% 1992 

USA 0.5% 1990 

Finland 0.51% 1992 

UK 0.6% 1992 

Netherlands 0.7% 1990 

Cuba 0.8% 1992 

Guadeloupe 0.8% 1992 

Malta* 1.01% 1993 

Italy (South) 1.37% 1989 

Spain 1.5% 1990 

* ELISA-2 screening; confirmed 0.04% 
Intrafamilial spread by social contact has not been 
proven, but mother-to-infant transmission occurs in 
some 10% of seropositive mothers, commonly when the 
mother is co-infected with HIY, and when HCY titres 
are high 7.8. 
Sexual transmission is probably negligible or rare 
(Table 2): two studies in low prevalence areas showed 
no evidence of transmission9.10. 
Diagnosis and screening 
As serological tests for hepatitis A and hepatitis B 
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Table 2 - Co-prevalence of anti-HCV jn spouses 
of HCV-positive cases' 
Country 	 HCV-positive Year of 
spouses / index publication 
USA 
Spain 
Finland 
USA 
(muiticentre) 
Japan 
Taiwan 
Italy 
USA/ltaly/ 
Australia 
Netherlands 
case 
0/40 1990 
5/71 1990 
0/30 1991 
5/194 1991 
14/176 1992 
5/25 1992 
13/83 1992 
3/106 1992 
0/50 1993 
became commercially available by the mid-seventies I I , 
non-A non-B hepatitis remained essentially a diagnosis 
of exclusion until 1990 when the first specific test for 
anti-HCV antibodies (ELISA-l) was introduced l2 . With 
time, test sensitivity II and specificity l3 were improved, 
and supplementary tests using recombinant immunoblot 
assay technology were developed 11. The move from 
ELISA-l to ELISA-2 shifted detectibility for anti-HCV 
from 90% to close to 100%14. The first reports on alpha 
interferon treatment for NANBH appeared in 1986 15 , 
and the RNA genome of hepatitis C first described in 
1989 16. Hepatitis C virus is associated with 90% of non­
A non-B hepatitis3. 
The Maltese perspective 
As in the rest of the world, commercial blood testing 
for hepatitis C only became available in Malta in the 
early nineteen-nineties. Epidemiological description has 
been problematic due to the high frequency of 
asymptomatic infections, and practical difficulties in 
investigating infection with connotations of socially 
undesirable acti vi ty. 
Data collection 
The term 'serum hepatitis' used in statutory notification 
of hepatitis in Malta17 does not distinguish between 
hepatitis B and C. Time trends derived from official 
figures of notified disease l8 (Table 3) may suffer from 
substantial artefactual variation due to inconsistent 
notification practices amongst clinicians over the years. 
While anonymity may encourage more persons at risk 
to test, it limits the possibility for epidemiological 
surveillance. The codification used for anonymous 
testing is non-standard and so repeat testing cannot be 
easily differentiated from fresh testing by surveying 
laboratory records alone. 
Virology laboratory, St. Luke's Hospital 
Diagnostic anti-HCV testing became available at the 
Malta state health services in 1992 19. The tests 
employed recombinant antigens which overcame initial 
problems of low sensitivity and specificity of earlier 
tests. ELISA-3 has been introduced very recently at the 
Virology Laboratory. Supplemental tests, including 
recombinant immunoblot assays (RIBA), are also 
performed. Common reasons for testing include IDU, 
sexual exposure, investigation of jaundice, deranged 
liver function, post-transfusion and pre-dialysis. From 
January 1994 to April 1997, 431 individuals are known 
to have reacted positive for HCV at Virology 
Laboratory, SLH. 80% were males and the main 
identified risk factor is IDUI9. 
Blood transfusion & organ donation 
In Malta, ELISA-2 is used by the Blood Transfusion 
Department for anti-HCV screening: initial positives are 
subjected to 3-8 further tests to minimise false positives2. 
Anti-HCV screening of blood products started in March 
1992. HCV antibodies were detected in 2.9-4.7 per 
10,000 donations over the period 1992-1994. As blood 
is nowadays fractioned into several products, screening 
for hepatitis C helped avert an estimated 4 to 24 primary 
infections per year over this period. 
Intravenous drug use 
The size of the local IDU population is undetermined. 
A total of 1074 users have been registered with the 
Detoxification Unit, SLH20. IDUs started being 
screened for anti-HCV in December 1993. 316 were 
tested by August 1996: 48% were anti-HCV positive. 
65% of 104 users testing through the anti-drug NGO 
CARIT AS were also anti-HCV positive21 . In contrast, 
only 3% of newly admitted drug addicts tested at 
Detoxification Centre, Malta over 1992-93 were HBsAg 
positive22 . 
Users of formal drug rehabilitation programmes are 
almost certainly a non-representative fraction of the 
underlying IDU population: grapevine reports hint at 
unreached pockets of users, circumscribed by age, 
location (eg. newly built areas) and social status (both 
extremes)23. 
Anecdotal reports (to the author) indicate HCV 
transmISSIOn in Malta going back at least to the mid­
1980s, and occurring as recent as 1996, and presumably 
extending also to the present. 
Prisons 
Prisoners may be at risk of hepatitis through injecting 
drugs, skin piercing and sexual activity. Prison 
Table 3 - Notified cases of serum hepatitis and AIDS, Maltese residents, 1988-96 
1988 1989 1990 1991 1992 1993 1994 1995 1996 
NANBH 3 3 I 1 6 7 5 2 
HBV 10 9 10 18 13 14 8 5 2 
AIDS 8 o I 7 4 3 5 3 4 
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authorities worldwide differ in their efforts to prevent hepatitis which present with classical features in the 
bloodborne infections, but in most countries, persons in acute or subacute stage. 
prison are afforded less protection against infection than Following current recommendations, in Malta, patients 
those outside24 (Table 4). with deranged liver function and histological proof of 
active hepatitis are considered for alphaTable 4 - Prison health policies in Malta and around the world 24,25 
Australia 
England 
France\ Germany 
! India 
Israel 
Malta 
Methadone 
treatment 
t/ 
t/ 
t/ 
t/ 
n/a 
t/ 
t/ 
Netherlands t/ 
Scotland t/ 
Thailand )( 
US t/ 
Condom Needle 
provision exchange 
•t/ )( 
t/ 
t/ 
)( 
)( 
)( 
t/ 
)( 
)( 
t/ 
t/ Yes/Some 
)( No 
)( 
)( 
n/a 
)( 
)( 
)( 
•
t/ 
)( 
)( 
n/a 
• Cleaning facilities in some Alpha interferon treatment has its 
interferon treatment. Treatment guidelines 
have been formulated and are, at present, 
Voluntary being piloted, Apart from disease criteria, Education Segregation 
for inclusion, patients with a history ofofHIV+ves testing 
drug use have to be clean of abuse for at t/ )( t/ 
least six months before start of treatment.t/ )( t/ 
The regimen currently adopted locally uses n/a )( t/ 
three mega Units of alpha interferon byt/ t/ t/ 
sub-cutaneous injection three times at/ t/ )( 
week. Duration of treatment is generallyt/ t/ t/ 

t/ n/a t/ 12 months: however this may be extended, 

as recent studies suggest that outcomes can t/ n/a t/ 

t/ )( t/ improve with regimens spread out 

n/a t/ t/ longer27. Optimisation stands to be 
t/ n/a t/ determined. Quantitative measurement of 
HCV RNA, though costly, is a useful tool 
Notapplicable/available in determining prognosis or evaluating 
response to therapy 14. 
Anti-HCV testing was introduced in Malta's Corradino 
Correctional Facilities in 1994. Testing is voluntary and 
coupled with incentives of free basic routine 
immunisation and inclusion in drug rehabilitation 
programmes25 . In February 1997, 46% of 251 inmates 
were anti-HCV positive26. The raised HCV 
seroprevalence noted in this setting is confounded by a 
high proportion of inmates with past or concurrent 
history of IOU. 
Other risk areas 
There is no data available on occupational and 
iatrogenic transmission of hepatitis C in Malta. Ad hoc 
studies in this area are not prioritised given no standard 
eradicative treatment as yet for asymptomatic carriage. 
There is also risk of infection from skin 
instrumentation at tattooing, cosmesis, electrolysis, 
bodypiercing and acupuncture. Skin instrumentation has 
not been independently linked to HCV infection in 
Maltese seropositives. 
Although mother-to-child transmiSSIOn has yet to be 
documented in Maim, the likelihood of its occurrence 
may increase as more of our females with a history of 
intravenous drug use bear children, mirroring the 
experience in vertical HIV -1 transmission in countries 
where IOU is an important component of HIV 
transmission . Local experience in paediatric hepatitis C 
is limited. 
Clinical perspective 
In Malta, patients with hepatitis C coming to treatment 
are picked up largely through screening of IDUs and 
prison inmates, or from follow-up investigations for 
abnormal liver function tests. Most are asymptomatic 
with only minimally raised transarninases indicative of 
ongoing hepatitis. This is in contrast with other forms of 
drawbacks: apart from the cost (thrice 
weekly injection for 12 months tops 
Lm 1,000 in medicinal costs alone28), 
adverse effects are quite common. These include flu­
like symptoms, depression and neutropenia29 , A full 
evaluation of response to treatment (which would 
include key quality of life measures) is in order for 
patients undergoing care. 
Conclusion 
In conclusion, a case is made for prioritising hepatitis 
C in Malta as a formidable emerging concern, which will 
have a significant impact on health resources. The 
following summary recommendations are being made 
based on greatest scope for action. 
1. Safe practices at transfusion and organ donation. 
It is essential to ring-fence this priority area given that: 
• efficiency of infection via this route is high 
• fractioning of blood products means one infected 

donation can affect several recipients 

• infection acquired post-donation has become highly 

unacceptable more so for conditions which can be 

detected 

2. Preventive action in other risk areas. 
Efforts should be directed at educating IDUs on safe 
practice, and risks of needle sharing. The policy of 
distributing syringes freely should be upheld, The 
management of correctional facilities will increasingly 
have to face in-prison transmission of bloodborne 
conditions, and pressures to stream inmates by crime 
category or serostatus. 
Preventive action is labour-intensive, involving contact 
tracing, pre- and post-test counselling, testing and 
referral. Given the occurrence of associated risk locally 
(IOU, sexual exposure), there is sufficient scope to 
customise services towards preventive action coupled 
with AIDS education, and in conjunction with other 
sectors outside the formal health services. 
1 
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Regulatory functions remain necessary to uphold sterile 
practice in areas like dentistry, other surgery, tattooing 
and beauty therapy. 
3. Occupational risk management 
Workers occupationally exposed to blood and blood 
products may be at increased risk of acquiring hepatitis 
through their work. An infected worker can then 
transmit infection to patients treated. If the litiginous 
setting stands to intensify , this would have to be 
addressed. Infected workers will have to be suspended 
from performing interventions with high risk of viral 
transmiSSIOn, with attendant loss of hard-gained 
expertise. Universal precautions in risky patient-worker 
interactions remains important. 
4. Epidemiological survey and analysis 
There is clear scope for focusing studies in specific risk 
areas. Such might include seroprevalence surveys of 
those multiply-transfused in the pre-screening era and 
offspring of women at risk or with confirmed HeV. 
Known associated conditions which may be of local 
relevance and amenable to study include subjects with 
thalassaemia, haemophilia, and on dialysisl4. 
Serial testing of comparable populations over time (eg 
blood donors, IDUs or antenatal females) could be a 
useful indicator of extension of infection over time. 
Unlinked anonymous studies would help estimate 
seroprevalence in various at-risk subgroups not generally 
in contact with the health services. 
5. Patient care 
Dedicating care services through a centralised liver 
clinic is expected to concentrate expertise, ensure better 
adherence to evaluated protocols and enhance academic 
pursuit. This should promote uniform eligibility and 
management modalities based on evidence rather than 
idiosyncrasy and routine habit. The possible stigma 
connotations of a 'liver clinic' have to be recognised. 
Therapy with new and expensive chemotherapy has also 
to be viewed in the light of its 'transplant-sparing' effect, 
as these interventions incur very high costs to patients 
and services. 
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